Mode
Text Size
Log in / Sign up
N/A N=50 Other

A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies

Non-Small Cell Lung Cancer

Enrolled (actual)
50
Serious AEs
10.0%
Results posted
Dec 2018
Primary outcome: Primary: Incidence of Intra-Operative Hemostatic Interventions — 1.8 Percentage of vessel transections

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ethicon, Inc.
Primary completion
May 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of Intra-Operative Hemostatic Interventions
1.8
PRIMARY
Post-operative Interventions or Procedures Related to Pulmonary Artery or Pulmonary Vein Bleeding

Summary

The primary objective of this trial is to demonstrate the effectiveness of the powered vascular stapler for transection of the pulmonary artery (PA) and pulmonary vein (PV) during Video-Assisted Thoracoscopic Lobectomy.

Eligibility Criteria

Inclusion Criteria

  • Subjects with a confirmed or suspected diagnosis of stage IA to stage IIB non-small cell lung cancer scheduled for lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)7;
  • Subjects scheduled for VATS lobectomy in accordance with their institution's SOC;
  • Performance status 0-1 (Eastern Cooperative Oncology Group classification);
  • ASA score < 3;
  • No prior history of VATS or open lung surgery (on the lung in which the procedure will be performed);
  • Willing to give consent and comply with study-related evaluation and treatment schedule; and
  • 18-75 years of age (inclusive).

Exclusion Criteria

  • Active (subject currently receiving systemic treatment) bacterial infection or fungal infection;
  • Systemic administration (intravenous or oral) of steroids, including herbal supplements that contain steroids (within 30 days prior to study procedure);
  • Uncontrolled diabetes mellitus;
  • End stage renal or liver disease;
  • History of severe cardiovascular disease;
  • FEV1% <50% or severe COPD;
  • Prior chemotherapy or radiation for lung cancer;
  • Scheduled concurrent surgical procedure other than diagnostic wedge resection followed by lobectomy (central venous access - e.g., port placement, mediastinoscopy with lymph node sampling, and VATS lymphadenectomy are allowed);
  • Robotic-assisted procedure;
  • Women who are pregnant or lactating at the time of screening;
  • Physical or psychological condition which would impair study participation;
  • The subject is judged unsuitable for study participation by the Investigator for any other reason;
  • Participation in any other investigational drug (within 30 days or 5 half-lives of an investigational drug) or device study; or
  • Unable or unwilling to attend follow-up visits and examinations.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03056300). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search